Drug Trial Radar · NCT05393440
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Apr 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
18
Planned (sponsor's estimate)
Start
Sep 16, 2022
Primary completion
Dec 31, 2023
Study completion Jul 1, 2024
Sponsor
- Lead sponsor
- Zhongnan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Binhui Biopharmaceutical Co., Ltd.
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.
Conditions
- Uterine Cervical Neoplasms
Interventions
BS-006Biological
BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximal tolerable doseTime frame: 2 months after initiation of enrollment
- Rate and grade of adverse eventsTime frame: From enrollment to 90 days after last treatment of all subjects
- Cope numbers of BS-006Time frame: 1 hours predose and 0.5 hours post-dose for first three doses and 1 hours predose ever after
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.